Avid Bioservices, Inc. (CDMO) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a challenging financial situation with a significant increase in net loss due to income tax provisions. Despite positive developments like new project agreements and expansion, the lack of clear guidance and management's vague responses in the Q&A raise concerns. The market strategy and shareholder return plan seem weak, with no significant positive catalysts. Adjusted for these insights, the overall sentiment is negative, likely leading to a stock price decrease of -2% to -8% over the next two weeks.
Key Financial Performance
Quarterly Revenues $43 million, representing an 8% increase compared to $39.8 million in the same prior year period. The increase was primarily due to increases in the mix and scale of manufacturing runs and process development services associated with new programs.
Annual Revenues $139.9 million, a decrease of approximately 6% compared to $149.3 million in the same prior year period. The decrease was primarily attributed to fewer manufacturing runs, a reduction in process development services from early stage programs, and a reduction of revenue for changes in estimated variable consideration under a contract.
Quarterly Gross Profit $5.5 million or 13% gross margin, compared to $8.4 million or 21% gross margin in the fourth quarter of fiscal 2023. The decrease was primarily driven by fewer manufacturing runs, partially offset by increases in the mix and scale of manufacturing runs and an increase in costs related to capacity expansions.
Annual Gross Profit $7.3 million or 5% gross margin, compared to $31.5 million or 21% gross margin for the 2023 full fiscal year. The decrease was driven by fewer manufacturing runs, a reduction of process development services, and increased costs related to expansions.
Quarterly SG&A Expenses $6.8 million, a decrease of 10% compared to $7.6 million in the fourth quarter of fiscal 2023. The decrease was primarily due to reductions in compensation and benefit-related expenses, facility expenses, and consulting fees.
Annual SG&A Expenses $26 million, a decrease of approximately 7% compared to $27.9 million in the same prior year period. The decrease was primarily due to reductions in compensation and benefit-related expenses, facility expenses, and consulting fees.
Quarterly Income Tax Expense $117.9 million, an increase compared to $0.9 million in the fourth quarter of fiscal 2023. The increase was due to a valuation allowance of $118.5 million against deferred tax assets.
Annual Income Tax Expense $113.8 million, an increase compared to $1.3 million for the prior year period. The increase was due to the valuation allowance recorded against deferred tax assets.
Quarterly Net Loss $123.1 million or $1.94 per basic and diluted share, compared to a net loss of $0.3 million or $0.01 per basic and diluted share for the fourth quarter of fiscal 2023. The significant increase in net loss was primarily due to the income tax provision recorded.
Annual Net Loss $140.8 million or $2.23 per basic and diluted share, compared to net income of approximately $0.3 million or $0.00 per basic and diluted share during the same prior year period. The increase in net loss was primarily due to the income tax provision recorded.
Quarterly Adjusted Net Loss Approximately $4.6 million or $0.07 per basic and diluted share, excluding the income tax provision recorded due to the valuation allowance.
Annual Adjusted Net Loss Approximately $22.3 million or $0.35 per basic and diluted share for the full fiscal year 2024, excluding the income tax provision recorded.
Cash and Cash Equivalents $38.1 million on April 30, 2024, compared to $38.5 million on April 30, 2023.
Operating Highlights
New Project Agreements: Signed multiple new project agreements totaling $30 million during the fourth quarter.
New Facilities: Completed and launched a new cell and gene therapy manufacturing facility.
Revenue Guidance: Provided revenue guidance for fiscal 2025 of $160 million to $168 million, representing a 17% growth year-over-year.
Backlog: Ended the fiscal year with a strong backlog of $193 million.
Capacity Expansion: Expanded annual revenue-generating capacity from approximately $120 million in fiscal 2021 to over $400 million today.
Gross Margin Improvement: Achieved an approximate doubling of gross margin in Q4 compared to Q3.
Market Positioning: Positioned to better service new and existing biotech customers and address the needs of large pharma.
Sustainability Assessment: Engaged EcoVadis for sustainability evaluation, achieving a score of 56, placing in the 62nd percentile globally.
Risk or Challenges
Revenue Decrease: For the full fiscal year 2024, revenues decreased by approximately 6% to $139.9 million, attributed to fewer manufacturing runs and a reduction in process development services.
Gross Profit Decline: Gross profit for the fiscal year was $7.3 million (5% gross margin), down from $31.5 million (21% gross margin) in the previous year, primarily due to fewer manufacturing runs and increased costs from capacity expansions.
Valuation Allowance: A valuation allowance of $118.5 million was recorded against deferred tax assets due to a net loss in fiscal 2024, indicating potential challenges in realizing these assets.
Net Loss: The company reported a net loss of $140.8 million for fiscal 2024, a significant increase from a net income of approximately $0.3 million in the prior year, highlighting financial instability.
Customer Insolvency: A terminated project related to the insolvency of a smaller customer contributed to revenue reduction and financial challenges.
Regulatory and Market Conditions: The financial market's status impacted results, particularly in the first half of the fiscal year, indicating sensitivity to external economic factors.
Capacity Utilization: While capacity utilization is expected to increase, the company faces challenges in onboarding and executing new programs, which could affect future revenue and margins.
Guidance & Outlook
New Project Agreements: Signed multiple new project agreements totaling $30 million during the fourth quarter, ending the fiscal year with a strong backlog of $193 million.
Capacity Expansion: Completed and launched a new cell and gene therapy manufacturing facility, increasing annual revenue-generating capacity from approximately $120 million in fiscal 2021 to over $400 million today.
Sustainability Assessment: Engaged EcoVadis for sustainability evaluation, achieving a score of 56, placing the company in the 62nd percentile globally.
Revenue Guidance for FY 2025: Provided revenue guidance of $160 million to $168 million for fiscal year 2025, representing a 17% growth year-over-year at the midpoint.
Gross Margin Improvement: Expected increase in capacity utilization and gross margin, with Q4 gross margin approximately doubling compared to Q3.
Production Pipeline: Anticipated contributions from late-phase programs in the production pipeline, expected to enhance future stability and growth.
Shareholder Return Plan
Share Repurchase Program: None
Key Q&A
Earnings Word Cloud
CDMO Transcript
The earnings call reveals a mixed outlook. Financial performance shows modest revenue growth and improved gross margin, but rising SG&A expenses and a widened net loss raise concerns. The Q&A section highlights uncertainties in backlog burn rate and large pharma strategy. While new project agreements and capacity expansion are positive, financial instability and competition pose risks. The lack of a share repurchase program and unclear management responses further contribute to a neutral sentiment. Despite optimistic guidance and infrastructure investments, the absence of strong catalysts limits positive sentiment.
The earnings call summary and Q&A indicate a challenging financial situation with a significant increase in net loss due to income tax provisions. Despite positive developments like new project agreements and expansion, the lack of clear guidance and management's vague responses in the Q&A raise concerns. The market strategy and shareholder return plan seem weak, with no significant positive catalysts. Adjusted for these insights, the overall sentiment is negative, likely leading to a stock price decrease of -2% to -8% over the next two weeks.
The earnings report reveals significant financial declines, including increased net losses and reduced cash reserves, despite a strong bookings backlog. The Q&A highlighted management's optimism but lacked specific guidance details, raising concerns. The company's market strategy, expenses, and financial health appear weak, with operating losses and declining margins. While there are some positive elements, like backlog growth and potential market opportunities, the overall sentiment is negative due to financial challenges and management's reluctance to provide clear guidance.
The earnings call revealed significant financial challenges, including a sharp decline in gross margins, increased net losses, and negative adjusted EBITDA. Despite a record backlog, revenue and margin issues persist, with management providing vague responses on revenue timelines. The market is likely to react negatively due to these financial setbacks and uncertainties, compounded by management's unclear guidance. However, the increased backlog and cash reserves may provide some cushion, preventing a strong negative impact.
CDMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
